RECOMBINANT PROTEIN EXPRESSION

Our protein expression platform encompasses three widely utilized systems: Escherichia coli (E. coli), yeast, and mammalian cells.

ANTIBODY DEVELOPMENT

Our antibody platform comprises traditional hybridoma-based monoclonal antibody (mAb) development and a bi-specific antibody engineering platform.

MODELING & EXPERIMENTATION

Our diverse modeling systems encompass proprietary reporter cell line models, conditionally regulated and stable cell lines, iPSC cell-derived 3D organoid models, syngeneic mouse tumor models, patient-derived xenograft (PDX) models, and transgenic mouse models.

MICROORGANISM-BASED CLEANTECH

By employing natural selection and genetic editing methodologies, we've developed a microbial-based platform. Through this, we've acquired highly proficient bioplastic-producing bacteria capable of utilizing industrial wastes (such as glycerin, fructose, and volatile fatty acids) as feedstock to yield high-volume bioplastic materials.

EXTRACTION & ANALYTICS

We have developed a technology platform tailored for the extraction and isolation of bioactive phytochemicals from diverse botanical sources, with a particular emphasis on cruciferous species. This platform is complemented by a high-performance liquid chromatography (HPLC) analytical system, enabling precise identification and quantitative analysis of targeted phytochemical constituents.

DRUG DELIVERY

We have devised polymer-based and chitosan-based methodologies for the formulation of nanomedicines, facilitating their targeted delivery to specific microenvironments. Furthermore, our drug formulation and delivery platforms empower us to engineer premium-grade nutraceutical and cosmeceutical products characterized by superior stability and bioavailability.